Table S1: All on-therapy adverse events and serious adverse events (safety population)

System organ class preferred term	All AEs, n (%)	SAEs,[a] n (%)
Any event	14 (93)	9 (60)
Cardiac disorders		
Any event	4 (27)	4 (27)
Acute myocardial infarction	1 (7)	1 (7)
Angina unstable	1 (7)	1 (7)
Cardiac arrest	1 (7)	1 (7)
Ventricular tachycardia	1 (7)	1 (7)
Infections and infestations		
Any event	5 (33)	3 (20)
Pneumonia	2 (13)	1 (7)
Urinary tract infection	2 (13)	0
Pneumonia mycoplasmal	1 (7)	1 (7)
Gastroenteritis viral	1 (7)	1 (7)
Influenza	1 (7)	0
Upper respiratory tract infection	1 (7)	0
Injury, poisoning, procedural complications		
Any event	4 (27)	2 (13)
Gastrointestinal stoma complication	1 (7)	1 (7)
Procedural hemorrhage	1 (7)	1 (7)
Arteriovenous fistula site complication	1 (7)	0
Arteriovenous fistula thrombosis	1 (7)	0
Vascular disorders		
Any event	4 (27)	2 (13)

Hematoma	1 (7)	1 (7)
Shock	1 (7)	1 (7)
Brachiocephalic vein stenosis	1 (7)	0
Venous stenosis	1 (7)	0
Gastrointestinal disorders		
Any event	4 (27)	1 (7)
Nausea	3 (20)	0
Lower gastrointestinal hemorrhage	1 (7)	1 (7)
Vomiting	1 (7)	0
Investigations		
Any event	3 (20)	0
Blood calcium decreased	1 (7)	0
Blood pressure increased	1 (7)	0
Occult blood positive	1 (7)	0
General disorder and administration site conditions		
Any event	2 (13)	0
Fatigue	1 (7)	0
Pyrexia	1 (7)	0
Metabolism and nutrition disorders		
Any event	2 (13)	0
Hyperkalaemia	1 (7)	0
Malnutrition	1 (7)	0
Respiratory, thoracic and mediastinal disorders		
Any event	2 (13)	0
Pleural effusion	2 (13)	0

Musculoskeletal and connective tissue disorders		
Any event	1 (7)	0
Pain in extremity	1 (7)	0
Nervous system disorders		
Any event	1 (7)	0
Sinus headache	1 (7)	0
Skin and subcutaneous tissue disorders		
Any event	1 (7)	0
Pruritus	1 (7)	0
Pruritus generalized	1 (7)	0

AE, adverse event; SAE, serious adverse event.
[a]Subset of all AEs that were serious.